Successful Treatment of Refractory Pemphigus Vulgaris with Ultra-Low-Dose Rituximab in a High-Risk Patient: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - Oct 18, 2026 - "Our case suggests that ultra‑low‑dose rituximab may be a safe and effective option for selected patients with refractory pemphigus vulgaris, particularly those with advanced age or cancer. Longer follow-up and further studies are needed to evaluate its long-term efficacy and safety."
Journal • Dermatology • Immunology • Oncology • Pain • Pemphigus Vulgaris
|
|
Guangdong Wen; Hui Wang; Kun Li; Yan Zhao; Yu Zhong; Zhanglei Mu
|